An oxazolidinone-type antibiotic
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cadazolid

Item No. 23030

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-cyclopropyl-6-fluoro-7-[4-[[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenoxy]methyl]-4-hydroxy-1-piperidinyl]-1-4-dihydro-4-oxo-3-quinolinecarboxylic acid
CAS Number
1025097-10-2
Synonyms
  • ACT-179811
Molecular Formula
C29H29F2N3O8
Formula Weight
585.6
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMF:PBS (pH 7.2) (1:5): 0.16 mg/mlDMSO: 20 mg/ml
λmax
240, 285 nm
SMILES
FC1=C(N2CCC(COC3=C(F)C=C(N4C[C@H](CO)OC4=O)C=C3)(O)CC2)C=C5C(C(C(C(O)=O)=CN5C6CC6)=O)=C1
InChi Code
InChI=1S/C29H29F2N3O8/c30-21-10-19-23(33(16-1-2-16)13-20(26(19)36)27(37)38)11-24(21)32-7-5-29(40,6-8-32)15-41-25-4-3-17(9-22(25)31)34-12-18(14-35)42-28(34)39/h3-4,9-11,13,16,18,35,40H,1-2,5-8,12,14-15H2,(H,37,38)/t18-/m1/s1
InChi Key
XWFCFMXQTBGXQW-GOSISDBHSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $153

    Add

    10 mg

    $268

    Add

    25 mg

    $587

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Cadazolid is an oxazolidinone-type antibiotic that has activity against a panel of C. difficile strains, including those resistant to fluoroquinolones and linezolid (Item No. 15012; MICs = 0.125-0.5 μg/ml).1 It inhibits toxin A and B formation in stationary-phase cultures and spore formation in late exponential cultures of the toxigenic C. difficile strain ATCC 9689. Cadazolid inhibits C. difficile protein synthesis (IC50s = 0.08-0.31 μg/ml) without affecting nucleic acid or cell wall synthesis (IC50s = 12-18.6 and >32 μg/ml, respectively).2 In vivo, cadazolid (1 and 10 mg/kg) increases survival in a mouse model of C. difficile-associated diarrhea (CDAD). It also confers 100% survival in a hamster model of CDAD when administered at doses greater than 3 mg/kg.1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Locher, H.H., Seller, P., Chen, X., et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob. Agents Chemother. 58(2), 892-900 (2014).

    2. Locher, H.H., Caspers, P., Bruyère , T., et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob. Agents Chemother. 58(2), 901-908 (2014).